Vivus

Vivus’ Qsymia beats out weight loss competitors in pricing watchdog's latest cost-effectiveness analysis
Vivus’ Qsymia beats out weight loss competitors in pricing watchdog's latest cost-effectiveness analysis
Endpoints
Vivus
Qsymia
weight loss
ICER
Novo Nordisk
Saxenda
Wegovy
Flag link:
A decade after its first approval, FDA expands weight loss pill's label for use in adolescents
A decade after its first approval, FDA expands weight loss pill's label for use in adolescents
Endpoints
Vivus
Qsymia
teens
FDA
obesity
Flag link:
Acceleron’s post-Reblozyl plan comes together
Acceleron’s post-Reblozyl plan comes together
EP Vantage
Acceleron
sotatercept
PAH
JNJ
Bellerophon Therapeutics
United Therapeutics
Vivus
Arena
Novartis
Flag link:
Vivus, diving into the cystic fibrosis sphere, backs stadium step-climbing fundraiser
Vivus, diving into the cystic fibrosis sphere, backs stadium step-climbing fundraiser
Fierce Pharma
Vivus
cystic fibrosis
Pancreaze
Flag link:
Moving Beyond Obesity, Vivus Strikes $135M Deal for Digestive Drug
Moving Beyond Obesity, Vivus Strikes $135M Deal for Digestive Drug
Xconomy
Vivus
Qsymia
Pancreaze
Janssen
Flag link:
Vivus Inc. stock rises 4.6% after regaining certain commercial rights for Stendra from Sanofi
Vivus Inc. stock rises 4.6% after regaining certain commercial rights for Stendra from Sanofi
Marketwatch
Vivus
Stendra
Sanofi
erectile dysfunction
Flag link:
Vivus reports 3Q loss
Vivus reports 3Q loss
Yahoo/AP
Vivus
earnings
Flag link:
Post-Endo pact, will Vivus go it alone on U.S. Stendra marketing--and should it?
Post-Endo pact, will Vivus go it alone on U.S. Stendra marketing--and should it?
Fierce Pharma
Vivus
Stendra
erectile dysfunction
Endo
Flag link:
Vivus Announces Positive Ruling In Qsymia Litigation - Will It Matter?
Vivus Announces Positive Ruling In Qsymia Litigation - Will It Matter?
Seeking Alpha
Vivus
Qsymia
obesity
Flag link:
Vivus: Qsymia Sales Close Out Q2 With Worst Sales Volume In 2 Years
Vivus: Qsymia Sales Close Out Q2 With Worst Sales Volume In 2 Years
Seeking Alpha
Vivus
Qsymia
obesity
Flag link:
Vivus - Qsymia Sales Still Trending In The Wrong Direction
Vivus - Qsymia Sales Still Trending In The Wrong Direction
Seeking Alpha
Vivus
Qsymia
obesity
Flag link:
Orexigen struggles to stay afloat as obesity market stagnates
Orexigen struggles to stay afloat as obesity market stagnates
BioPharma Dive
Orexigen
obesity
Contrave
Vivus
Qsymia
Takeda
Flag link:
Arena Investors: What To Consider As Anti-Obesity Drugs Fizzle
Arena Investors: What To Consider As Anti-Obesity Drugs Fizzle
Seeking Alpha
Arena Pharmaceuticals
obesity
Orexigen
Belviq
Eisai
Vivus
Novo Nordisk
Qsymia
Victoza
Flag link:
Orexigen: Contrave Sales Flatten Out At End Of Q1
Orexigen: Contrave Sales Flatten Out At End Of Q1
Seeking Alpha
Orexigen
Contrave
obesity
Novo Nordisk
Vivus
Arena Pharmaceuticals
Flag link:
Vivus posts 4th-quarter loss of $12.2 million
Vivus posts 4th-quarter loss of $12.2 million
Yahoo/AP
Vivus
earnings
Flag link:
Hoping Vivus and Orexigen can finally kick-start their obesity meds? Don't count on it, analyst says
Hoping Vivus and Orexigen can finally kick-start their obesity meds? Don't count on it, analyst says
Fierce Pharma Marketing
obesity
Vivus
Orexigen
Contrave
Qsymia
Takeda
Flag link:
Vivus- Were Qsymia Patents Strong Enough? Actavis Stance Questions That
Vivus- Were Qsymia Patents Strong Enough? Actavis Stance Questions That
Seeking Alpha
Vivus
Qsymia
patents
Actavis
Flag link:
Belviq Sales Close Out 2015 With A Slump
Belviq Sales Close Out 2015 With A Slump
Seeking Alpha
Belviq
Arena Pharmaceuticals
obesity
Vivus
Orexigen
Flag link:
Endo opts of licensing deal for ED drug
Endo opts of licensing deal for ED drug
Bizjournals.com
Endo International
Stendra
Vivus
erectile dysfunction
Flag link:
Vivus reports 3Q loss
Vivus reports 3Q loss
Yahoo/AP
Vivus
earnings
Flag link:

Pages